

NEWSLETTER September – October 2019

CEO's greetings

We are frequently asked about our planned dual listing in Nasdaq First North Sweden. While we haven't disclosed any details, we have announced that we plan to complete the dual listing by the end of the year. It's the last quarter already so please remain patient...

Speaking of the turn of the year: Our Parkinson's Phase 1-2 study is fully recruited and scheduled for unblinding in Q1. Patient recruitment in our Phase 2 AdeLE study with Lymfactin® continues to target end-of-year completion, leading to blinded follow-up of 12 months before unblinding. So, we are looking forward to 2020 as the most exciting year in the history of Herantis!

Amid the hard development work our web site has been completely updated. We hope it makes it even easier for patients, investors, and other stakeholders to find the information they are looking for. Welcome to the new Herantis.com!

CLINICAL STUDIES

- **Breast Cancer Associated Lymphedema:** Phase 2 study AdeLE is actively recruiting patients in Sweden and Finland. See [Lymfactin web site](#) for more information.
- **Parkinson's disease:** Phase 1-2 study with CDNF ongoing and fully recruited.
- **Breast Cancer Associated Lymphedema:** Phase 1 study in long-term follow-up, active treatments concluded.

PLANNED ACTIVITIES

- **Nasdaq Nordic event**, 7 Nov 2019 at Erik Penser Bank, Stockholm: Company presentation to Swedish investors
- **BioEurope**, 11-13 Nov 2019: International partnering event in Hamburg, Germany
- **Avanza Börsdag**, 19 Nov 2019 in Stockholm: Company presentation to Swedish investors
- **RedEye Life Science Day**, 19 Nov 2019 in Stockholm: Company presentation to Swedish investors
- **Vator Unicorn Summit**, 27 Nov 2019 in Stockholm: Company presentation and meetings with life science investors
- **San Antonio Breast Cancer Symposium®**, 10-14 Dec 2019 in San Antonio, Texas, USA: Herantis' Lymfactin® poster presentation
- **JP Morgan Healthcare Conference**, 13-16 Jan 2020 in San Francisco: Meetings with potential partners, investors, and other healthcare professionals

Herantis of the month



Proud to promote Finland's beautiful landscape on our new website!

Keep up-to-date on Herantis:



Highlights from our team

Sigrid and Henri participated in MDS, the international Movement Disorder Society congress in Nice, France in September. Busy days full of interesting discussions with leading experts in Parkinson's disease, including a get-together with the clinical investigators of our Phase 1-2 study. The weather was nice too ☺

Topics of interest

Edison Investment Research published an update report on Herantis dated 2nd Sep 2019. The report can be found on our [Analyst Coverage page](#).

Ethical aspects are very important in drug development and clinical practice. They are often also very challenging. In recognition of UNESCO's World Bioethics Day, the topic of bioethics was covered in [our recent blogging](#).

Herantis in the news

The 'Financial Times of Finland', Kauppalehti, interviewed Herantis' CEO Pekka Simula as [Person of the Week on Sep 9th](#) (in Finnish).

Sweden's EFN TV interviewed [professional life science investors](#) (in Swedish). Herantis was named as one of 'three favorite Nordic pharmaceutical companies.'